A Friedman

Summary

Affiliation: Medical University of Warsaw
Country: Poland

Publications

  1. ncbi request reprint Botulinum toxin for treatment of parkinsonian sialorrhea
    A Friedman
    Department of Neurology, Medical University of Warsaw, Warsaw, Poland
    Neurol Neurochir Pol 35:23-7. 2001
  2. doi request reprint Iron as a cause of Parkinson disease - a myth or a well established hypothesis?
    Andrzej Friedman
    Department of Neurology, Medical University in Warsaw, Poland
    Parkinsonism Relat Disord 15:S212-4. 2009
  3. doi request reprint Paroxysmal non-kinesigenic dyskinesia caused by the mutation of MR-1 in a large Polish kindred
    Andrzej Friedman
    Department of Neurology, Faculty of Health Science, Medical University in Warsaw, Warsaw, Poland
    Eur Neurol 61:39-41. 2009
  4. ncbi request reprint [Are dopamine agonists alternative therapy for levodopa in early stage of Parkinson's disease? No]
    Andrzej Friedman
    Katedra i Klinika Neurologii Wydziału Nauki o Zdrowiu, Akademia Medyczna w Warszawie
    Neurol Neurochir Pol 41:S10-3. 2007
  5. ncbi request reprint Iron and ferritin in hippocampal cortex and substantia nigra in human brain--implications for the possible role of iron in dementia
    Andrzej Friedman
    Department of Neurology, Medical University of Warsaw, Poland
    J Neurol Sci 248:31-4. 2006
  6. doi request reprint Ferritin as an important player in neurodegeneration
    Andrzej Friedman
    Department of Neurology, Medical University in Warsaw, ul Kondratowicza 8, 03 242 Poland
    Parkinsonism Relat Disord 17:423-30. 2011
  7. ncbi request reprint Quality of life in Polish patients with long-lasting Parkinson's disease
    Marcin Zach
    Department of Neurology, Medical University of Warsaw, Warsaw, Poland
    Mov Disord 19:667-72. 2004
  8. ncbi request reprint ELISA reveals a difference in the structure of substantia nigra ferritin in Parkinson's disease and incidental Lewy body compared to control
    Dariusz Koziorowski
    Department of Neurology, The Medical University in Warsaw, ul Kondratowicza 8, 03 242 Warsaw, Poland
    Parkinsonism Relat Disord 13:214-8. 2007
  9. doi request reprint A family with paroxysmal nonkinesigenic dyskinesia: genetic and treatment issues
    Krzysztof Szczałuba
    Department of Medical Genetics, Institute of Mother and Child, Faculty of Health Science, Medical University in Warsaw, Warsaw, Poland
    Pediatr Neurol 41:135-8. 2009
  10. ncbi request reprint Levodopa "drug holiday" with amantadine infusions as a treatment of complications in Parkinson's disease
    Dariusz Koziorowski
    Department of Neurology, The Medical University of Warsaw, Warsaw, Poland
    Mov Disord 22:1033-6. 2007

Collaborators

Detail Information

Publications19

  1. ncbi request reprint Botulinum toxin for treatment of parkinsonian sialorrhea
    A Friedman
    Department of Neurology, Medical University of Warsaw, Warsaw, Poland
    Neurol Neurochir Pol 35:23-7. 2001
    ..Most of the medications used for the treatment of it are ineffective. We decided to try in such patients local injections of botulinum toxin, type A, into both parotid glands...
  2. doi request reprint Iron as a cause of Parkinson disease - a myth or a well established hypothesis?
    Andrzej Friedman
    Department of Neurology, Medical University in Warsaw, Poland
    Parkinsonism Relat Disord 15:S212-4. 2009
    ..This finding corresponds well to a decrease of L-ferritin concentration in parkinsonian SN and also to a difference of the size of iron core of ferritin between PD and control SN. The significance of these finding will be discussed...
  3. doi request reprint Paroxysmal non-kinesigenic dyskinesia caused by the mutation of MR-1 in a large Polish kindred
    Andrzej Friedman
    Department of Neurology, Faculty of Health Science, Medical University in Warsaw, Warsaw, Poland
    Eur Neurol 61:39-41. 2009
    ..In addition, at the age of 55 years, she developed symptoms of Parkinson's disease with good response to levodopa treatment...
  4. ncbi request reprint [Are dopamine agonists alternative therapy for levodopa in early stage of Parkinson's disease? No]
    Andrzej Friedman
    Katedra i Klinika Neurologii Wydziału Nauki o Zdrowiu, Akademia Medyczna w Warszawie
    Neurol Neurochir Pol 41:S10-3. 2007
    ..Therefore the treatment of Parkinson's disease should be started with levodopa...
  5. ncbi request reprint Iron and ferritin in hippocampal cortex and substantia nigra in human brain--implications for the possible role of iron in dementia
    Andrzej Friedman
    Department of Neurology, Medical University of Warsaw, Poland
    J Neurol Sci 248:31-4. 2006
    ..The size of the average iron core in Hip was assessed to be about 3.1 nm and about 3.7 nm in SN. These results may point to different iron metabolism in these areas, suggesting faster iron turnover in Hip...
  6. doi request reprint Ferritin as an important player in neurodegeneration
    Andrzej Friedman
    Department of Neurology, Medical University in Warsaw, ul Kondratowicza 8, 03 242 Poland
    Parkinsonism Relat Disord 17:423-30. 2011
    ..We discuss the importance of the ratio H/L ferritin and its changes in neurodegeneration...
  7. ncbi request reprint Quality of life in Polish patients with long-lasting Parkinson's disease
    Marcin Zach
    Department of Neurology, Medical University of Warsaw, Warsaw, Poland
    Mov Disord 19:667-72. 2004
    ..Duration of the disease and expenses related to the treatment also have a significant impact on the QoL. Patient's age and presence of dyskinesia seem to be irrelevant to the quality of life...
  8. ncbi request reprint ELISA reveals a difference in the structure of substantia nigra ferritin in Parkinson's disease and incidental Lewy body compared to control
    Dariusz Koziorowski
    Department of Neurology, The Medical University in Warsaw, ul Kondratowicza 8, 03 242 Warsaw, Poland
    Parkinsonism Relat Disord 13:214-8. 2007
    ..9+/-87.7) and control (374.8+/-169.3). The decrease of L ferritin in SN in PD and ILB may suggest that the whole process of neurodegeneration starts with a higher availability of free iron, which is released from the ferritin shell...
  9. doi request reprint A family with paroxysmal nonkinesigenic dyskinesia: genetic and treatment issues
    Krzysztof Szczałuba
    Department of Medical Genetics, Institute of Mother and Child, Faculty of Health Science, Medical University in Warsaw, Warsaw, Poland
    Pediatr Neurol 41:135-8. 2009
    ..Favorable response to levetiracetam is probably linked to action of the drug on calcium channels in neurons, muscle cells, or both...
  10. ncbi request reprint Levodopa "drug holiday" with amantadine infusions as a treatment of complications in Parkinson's disease
    Dariusz Koziorowski
    Department of Neurology, The Medical University of Warsaw, Warsaw, Poland
    Mov Disord 22:1033-6. 2007
    ..The improvement after therapy was maintained up to 4 month. The levodopa "drug holidays" with amantadine infusion is a valuable option in the therapy of advanced stages of PD...
  11. ncbi request reprint Controlling sialorrhoea: a review of available treatment options
    Anna Potulska
    Medical University, Warsaw, Department of Neurology, Poland
    Expert Opin Pharmacother 6:1551-4. 2005
    ..However, some cases of sialorrhoea are due to hypersecretion of saliva. These cases represent so-called primary sialorrhoea...
  12. doi request reprint Low frequency of the PARK2 gene mutations in Polish patients with the early-onset form of Parkinson disease
    Dariusz Koziorowski
    Department of Neurology, Faculty of Heath Science, Medical University of Warsaw, Kondratowicza 8, 03 242 Warsaw, Poland
    Parkinsonism Relat Disord 16:136-8. 2010
    ..Although the frequency of the PARK2 mutations in EO-PD patients according to several studies is high and has been reported in up to 50% in familial and 19% in sporadic cases, these data remain controversial...
  13. ncbi request reprint Swallowing disorders in Parkinson's disease
    Anna Potulska
    Department of Neurology, Medical University of Warsaw, ul Banacha 1a, 02 097 Warsaw, Poland
    Parkinsonism Relat Disord 9:349-53. 2003
    ..In the remaining five cases swallowing impairment was subclinical and it consisted of decreased dysphagia limit and prolongation of the esophageal phase. Dysphagia at the subclinical level may be one of the early symptoms of PD...
  14. ncbi request reprint Mössbauer spectroscopy and ELISA studies reveal differences between Parkinson's disease and control substantia nigra
    Jolanta Galazka-Friedman
    Faculty of Physics, Warsaw University of Technology, 00 662 Warsaw, Koszykowa 75, Poland
    Biochim Biophys Acta 1688:130-6. 2004
    ..Iron released from ferritin or neuromelanin (NM) may be the source of such iron, which may cause the difference in the Mössbauer spectra and may trigger oxidative stress leading to cell death...
  15. ncbi request reprint [Consensus regarding indications for surgical treatment of Parkinson disease]
    Andrzej Friedman
    Klinika Neurochirurgii Oddział Neurochirurgii Czynnościowej i Chorób Układu Pozapiramidowego Akademia Medyczna w Gdańsku ul Debinki 7, 80 211 Gdansk
    Neurol Neurochir Pol 37:11-7. 2003
    ....
  16. ncbi request reprint Nonverbal deficits in explicit and implicit memory of Parkinson's disease patients
    Ludwika Gawrys
    Laboratory for Molecular Neurobiology, Nencki Institute of Experimental Biology, Pasteura 3, 02 093 Warsaw, Poland
    Acta Neurobiol Exp (Wars) 68:58-72. 2008
    ..Interestingly, such a correlation was found in the case of MR and words pairs tasks, which did not distinguish PD patients from control group...
  17. ncbi request reprint [Deep brain stimulation and motor cortex and spinal cord stimulation in the treatment of movement disorders and pain syndromes -- the theoretical baseline and practical guidelines]
    Mirosław Zabek
    Oddział Neurochirurgii Czynnościowej i Chorób Układu Pozapiramidowego, Klinika Neurochirurgii, Akademia Medyczna, ul Debinki 7, 80 211 Gdansk
    Neurol Neurochir Pol 40:1-9. 2006
    ..Suggested selection criteria are based on experience of different centers and on current medical literature. They are published to make the procedure more rational and more available in Poland...
  18. ncbi request reprint [Swallowing disorders in Parkinson's disease]
    Anna Potulska
    Klinika Neurologii Akademii Medycznej w Warszawie
    Neurol Neurochir Pol 36:449-56. 2002
    ..Dysphagia was observed in all studied patients, although only 8 of them complained about it. In other 3 cases the impairment of swallowing was subclinical and it was connected with prolongation of oesophageal phase...
  19. ncbi request reprint [Dopa-responsive dystonia (Segawa variant): clinical analysis of 7 cases with delayed diagnosis]
    Jarosław Sławek
    Klinika Neurochirurgii Oddział Neurochirurgii Czynnościowej i Chorób Układu Pozapiramidowego, Akademia Medyczna w Gdansku
    Neurol Neurochir Pol 37:117-26. 2003
    ..The take home message from literature and presented material should be not age dependent clinical trial with levodopa therapy in all cases of dystonia starting in extremities...